How Does Semaglutide Work: GLP-1 Mechanism, Market Trends & Brand Efficacy Data
Published: July 12, 2026 22:32
Author: Deepa Martinez
Abstract: Semaglutide, a GLP-1 receptor agonist, mimics incretin hormones to regulate blood glucose and appetite, driving a multi-billion dollar peptide market. Clinical data from the STEP and SUSTAIN trials demonstrate superior efficacy (up to 15% weight loss) and cardiovascular benefits for Novo Nordisk’s Ozempic and Wegovy. Market trends show a 25% annual growth, with key differentiators in purity (>99%), stability, and cold-chain logistics. Brand comparison reveals higher patient adherence for branded versions versus compounded generics, which lack FDA approval. Selecting high-GMP-certified peptides with verified HPLC purity is critical for safety and efficacy in obesity and diabetes management.